JP7828661B2 - 避妊薬の化合物及び方法 - Google Patents

避妊薬の化合物及び方法

Info

Publication number
JP7828661B2
JP7828661B2 JP2023567167A JP2023567167A JP7828661B2 JP 7828661 B2 JP7828661 B2 JP 7828661B2 JP 2023567167 A JP2023567167 A JP 2023567167A JP 2023567167 A JP2023567167 A JP 2023567167A JP 7828661 B2 JP7828661 B2 JP 7828661B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023567167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516023A5 (https=
JP2024516023A (ja
Inventor
イングリッド グンダ ゲオルグ，
ナルシームル チェリヤラ，
Original Assignee
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティ オブ ミネソタ filed Critical リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Publication of JP2024516023A publication Critical patent/JP2024516023A/ja
Publication of JP2024516023A5 publication Critical patent/JP2024516023A5/ja
Application granted granted Critical
Publication of JP7828661B2 publication Critical patent/JP7828661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023567167A 2021-05-04 2022-05-03 避妊薬の化合物及び方法 Active JP7828661B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163184014P 2021-05-04 2021-05-04
US63/184,014 2021-05-04
US202263307943P 2022-02-08 2022-02-08
US63/307,943 2022-02-08
US202263326524P 2022-04-01 2022-04-01
US63/326,524 2022-04-01
PCT/US2022/027506 WO2022235693A1 (en) 2021-05-04 2022-05-03 Contraceptive compounds and methods

Publications (3)

Publication Number Publication Date
JP2024516023A JP2024516023A (ja) 2024-04-11
JP2024516023A5 JP2024516023A5 (https=) 2025-05-09
JP7828661B2 true JP7828661B2 (ja) 2026-03-12

Family

ID=81854578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567167A Active JP7828661B2 (ja) 2021-05-04 2022-05-03 避妊薬の化合物及び方法

Country Status (9)

Country Link
US (3) US11780828B2 (https=)
EP (1) EP4334309A1 (https=)
JP (1) JP7828661B2 (https=)
KR (1) KR20240004737A (https=)
AU (1) AU2022270088A1 (https=)
CA (1) CA3217096A1 (https=)
IL (1) IL308171A (https=)
MX (1) MX2023012958A (https=)
WO (1) WO2022235693A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法
WO2025251031A1 (en) * 2024-05-30 2025-12-04 Yourchoice Therapeutics, Inc. Contraceptive compounds and dosing for the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201200A1 (en) 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
JP2018505860A (ja) 2014-12-19 2018-03-01 ガルデルマ・リサーチ・アンド・デヴェロップメント 新規化合物、その合成方法、並びに医薬品及び化粧品におけるその使用
WO2019099949A1 (en) 2017-11-17 2019-05-23 The Regents Of The University Of California Manipulation of the retinoic acid signaling pathway
JP2020526539A (ja) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せた受容体サブタイプ及び機能に選択性を示すレチノイド及びレキシノイド化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CN1255396C (zh) * 1996-03-18 2006-05-10 卫材株式会社 含有稠环的羧酸衍生物
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505860A (ja) 2014-12-19 2018-03-01 ガルデルマ・リサーチ・アンド・デヴェロップメント 新規化合物、その合成方法、並びに医薬品及び化粧品におけるその使用
WO2017201200A1 (en) 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
JP2020526539A (ja) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せた受容体サブタイプ及び機能に選択性を示すレチノイド及びレキシノイド化合物
WO2019099949A1 (en) 2017-11-17 2019-05-23 The Regents Of The University Of California Manipulation of the retinoic acid signaling pathway

Also Published As

Publication number Publication date
US20250276962A1 (en) 2025-09-04
US20220388993A1 (en) 2022-12-08
US12281105B2 (en) 2025-04-22
AU2022270088A1 (en) 2023-11-23
EP4334309A1 (en) 2024-03-13
KR20240004737A (ko) 2024-01-11
CA3217096A1 (en) 2022-11-10
IL308171A (en) 2023-12-01
MX2023012958A (es) 2024-01-05
JP2024516023A (ja) 2024-04-11
US11780828B2 (en) 2023-10-10
US20240109872A1 (en) 2024-04-04
WO2022235693A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
RU2572818C2 (ru) Производное тетрагидрокарболина
TWI507410B (zh) 新穎磷酸二酯酶抑制劑
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
US20250276962A1 (en) Contraceptive compounds and methods
TW201630891A (zh) 三環性螺化合物
ES2587856T3 (es) Derivado de tetrahidrocarbolina
ES2987356T3 (es) Compuestos antiproliferación y usos de los mismos
WO2018188641A1 (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
KR20210141461A (ko) 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도
KR101233289B1 (ko) 지양제
AU2022244467A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP2021527048A (ja) 癌治療のためのアシル化カテキンポリフェノールおよびその使用方法
KR101901741B1 (ko) 세스터터핀 화합물 및 이들 물질의 용도
CN101657440B (zh) 异二聚体及其使用方法
WO2020156505A1 (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
US7071205B2 (en) 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
US20250333371A1 (en) Compounds
US11541046B2 (en) Spirolactone compounds
EP4499067A1 (en) Compounds for treating psychostimulant misuse
CN117881674A (zh) 避孕化合物和方法
CN101889014A (zh) 富含对映体的咪唑并吖庚因酮化合物
TW200307548A (en) Histamine-3 receptor ligands for diabetic conditions
WO2026092697A1 (zh) 一种苯并嘧啶类化合物、其制备方法和用途
JP2017537108A (ja) ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
WO2020259612A1 (zh) 一种抗抑郁甾体化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7828661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150